|
Dr. Mark DeWyngaert
Managing Director, Huron Consulting Group
Dr. DeWyngaert is a Managing Director in the Pharmaceutical & Life Sciences Advisory Practice at Huron Consulting Group. Mark trained as a molecular biologist and has been actively involved in both research and business development roles for the past 25 years. He has provided operational, clinical, managerial, consulting, and litigation services to various segments of the health care industry. He specializes in assisting pharmaceutical manufacturers, biotechnology, and medical device companies with identifying and mitigating regulatory risks and valuing intellectual property.
Mark regularly leads teams in the assessment of sales & marketing, medical affairs and clinical development activities and assists companies in the redesign of business practices to comply with applicable regulations and standards. Recently, Mark has assisted clients with compliance Aggregate Spending Initiatives around their clinical and medical affairs activities. He also serves clients and their legal counsel in fraud investigations, compliance inquiries, litigation strategy issues, and acts as an expert witness.
|
|
Ed Saltzman
President, DefinedHealth
Ed is founder and President of DefinedHealth, a leading consultancy in business development and disease area strategy for the pharmaceutical industry. Since its founding in 1983, DefinedHealth has completed thousands of opportunity assessments and commercial forecasts of development stage projects for hundreds of corporate clients across the Big Pharma, Biotechnology and Specialty Pharma complex. DefinedHealth`s length and breadth of experience in evaluating pipeline opportunities provides the firm with a unique and often unconventional spotlight on strategic issues confronting the industry, particularly with respect to the quality of the development pipeline and its implications for sustainability of established and evolving business models.
Ed is a noted speaker on industry strategy and was one of the earliest critics of the Pharma industry blockbuster business model and its over-dependence on in-licensing late-stage primary care blockbuster drugs to fuel growth. Ed was also one of the first to spot the limitation of the specialty pharma serial product acquisition model, and, as a result, he is much sought after for strategic guidance by specialty pharma and biotech companies facing sustainability challenges.
Ed began his involvement with the pharma industry at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing. Prior to Ayerst, he managed the Healthcare Information Center at FIND/SVP.
Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University.
|
Tamar D. Howson
MS, MBA, JSB Partners
Tamar has joined a transaction advisory firm, JSB-Partners in January 2009. Prior to JSB, Tamar has been a senior corporate and business development executive at several large pharmaceutical companies as well as Lexicon Pharmaceuticals, a biotech company. Between 2001 and 2007 Tamar was the SVP Corporate and Business Development at Bristol Myers Squibb overseeing M&A, licensing, research collaborations (Lexicon, Medarex, Pierre-Fabre, Solvay, Exelixis, Merck, Astra-Zeneca, etc.) across all businesses. In 2000 and 2001 Tamar was a business development and strategy consultant to several biotechnology companies, served as a Director for Ariad, NPS, SkyePharma and Targacept, a Special Limited partner at Care Capital and several advisory boards. Between 1991 and 2000, she was the VP and then SVP and Director of Worldwide Business and Corporate Development, for SmithKline Beecham. During her tenure at SB, her team signed numerous in- and out-licensing agreements and research collaborations. Between 1998 and 2000 she also managed SmithKline Beecham`s $100MM venture capital fund, SR One.
Before joining SmithKline, Tamar was a vice president of venture investments at Johnston Associates, a venture capital firm. Before that, she was Director of Worldwide Business Development and Licensing for Squibb Corporation.
Tamar holds a MBA from Columbia U., MS from CCNY and BS in ChemE from the Technion, Israel.
Christine T. Fischette
President, Enzo Therapeutics, Inc.
Christine has held this position since January 2008. Before her employment with Enzo, she was Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals, a division of Novartis Ag from 1999-2007. She held various positions of increasing responsibility at Pfizer Pharmaceuticals, NY and directed preclinical/clinical development, medical marketing, and was head of Pfizer`s US commercial arm for diabetes before joining business development and licensing from 1987-1999. Prior to her work experience at Pfizer, she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post-Doctoral Fellow at Rockefeller University. Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey and a B.A. in Biology Education from Rutgers University (1973).
|
Events
Add this event to Outlook